Medtronic(US:MDT) ZACKS·2026-02-11 15:16Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.33 per share, a decline of 4.3% year-over-year, with revenues projected at $8.9 billion, reflecting a 7.3% increase compared to the previous year [1] Revenue Estimates - Analysts estimate 'Net Sales- World Wide Revenue- Cardiovascular' to be $3.37 billion, indicating a year-over-year increase of 10.8% [4] - 'Net Sales- World Wide Revenue- Neuroscience' is projected to reach $2.59 billion, reflecting a 5.3% increase year-over-year [4] - 'Net Sales- World Wide Revenue- Neuroscience- Cranial & Spinal Technologies' is expected to be $1.32 billion, a 6% increase from the prior year [5] - 'Net Sales- World Wide Revenue- Neuroscience- Neuromodulation' is forecasted at $505.68 million, indicating a 6.2% year-over-year change [5] U.S. Revenue Estimates - 'Net Sales- U.S. Revenue' is anticipated to be $4.53 billion, suggesting a 6.9% increase year-over-year [6] - 'Net Sales- U.S. Revenue- Neuroscience- Neuromodulation' is projected at $342.56 million, reflecting a 4.8% increase [6] International Revenue Estimates - 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' is expected to reach $338.62 million, indicating a 10.3% year-over-year change [6] - 'Net Sales- ROW- Neuroscience- Specialty Therapies' is projected at $335.35 million, reflecting a 7.1% increase [7] - 'Net Sales- ROW- Cardiovascular- Cardiac Rhythm & Heart Failure' is expected to be $826.64 million, indicating a 7.4% increase [8] - 'Net Sales- ROW- Diabetes' is projected at $522.47 million, reflecting a significant 14.3% increase from the previous year [8] - The consensus estimate for 'Net Sales- ROW- Cardiovascular' stands at $1.77 billion, indicating an 8.5% year-over-year change [8] Stock Performance - Medtronic shares have shown a return of +5.2% over the past month, outperforming the Zacks S&P 500 composite, which has seen a -0.3% change [9]